By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion today updated a planned offering of its common stock to raise as much as $33.9 million.

In an amended S-1 filing with the US Securities and Exchange Commission, the Austin, Texas-based diagnostics company said that it plans to offer up to 4 million shares of its stock at a maximum price of $7.36 per share.

Roth Capital Partners, the underwriter on the planned offering, also has the option to purchase 600,000 shares to cover overallotments, if any.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.